Upcoming Dividend • May 14
Upcoming dividend of UK£0.015 per share Eligible shareholders must have bought the stock before 21 May 2026. Payment date: 22 June 2026. Payout ratio is on the higher end at 92%, however this is supported by cash flows. Trailing yield: 2.5%. Lower than top quartile of British dividend payers (5.8%). In line with average of industry peers (2.6%). Declared Dividend • Apr 27
Dividend increased to UK£0.015 Dividend of UK£0.015 is 24% higher than last year. Ex-date: 21st May 2026 Payment date: 22nd June 2026 Dividend yield will be 2.3%, which is about the same as the industry average. Sustainability & Growth Dividend is not adequately covered by earnings (92% earnings payout ratio). However, it is well covered by cash flows (46% cash payout ratio). The dividend has increased by an average of 24% per year over the past 2 years and payments have been stable during that time. The company's earnings per share (EPS) would need to grow by 1.9% to bring the payout ratio under control. EPS is expected to grow by 52% over the next 3 years, which is sufficient to bring the dividend into a sustainable range. Aankondiging • Apr 22
NIOX Group Plc, Annual General Meeting, May 21, 2026 NIOX Group Plc, Annual General Meeting, May 21, 2026. Location: the companys registered office magdalen centre, 1 robert robinson ave, the oxford science park, england, ox4 4ga, oxford United Kingdom Recent Insider Transactions Derivative • Apr 20
CEO & Executive Director exercised options and sold UK£183k worth of stock On the 16th of April, Jonathan Emms exercised 585.11k options at around UK£0.0008, then sold 325k of the shares acquired at an average of UK£0.56 per share and kept the remainder. For the year to December 2019, Jonathan's total compensation was 24% salary and 76% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since June 2025, Jonathan's direct individual holding has increased from 3.26m shares to 3.40m. Company insiders have collectively sold UK£4.6m more than they bought, via options and on-market transactions in the last 12 months. Major Estimate Revision • Apr 08
Consensus EPS estimates increase by 19% The consensus outlook for fiscal year 2026 has been updated. 2026 EPS estimate increased from UK£0.014 to UK£0.016. Revenue forecast steady at UK£50.2m. Net income forecast to grow 67% next year vs 43% growth forecast for Medical Equipment industry in the United Kingdom. Consensus price target broadly unchanged at UK£0.82. Share price fell 2.4% to UK£0.57 over the past week. New Risk • Mar 29
New minor risk - Dividend sustainability The dividend is not well covered by earnings. Payout ratio: 105% Dividend yield: 2.7% This is considered a minor risk. Companies that pay out too much of their earnings are at risk of having to reduce or cut their dividend in future. If earnings growth slows or earnings fall, then there may not be enough earnings to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. However, this risk is mitigated by the fact the dividend is covered by cash flows. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company. Reported Earnings • Mar 25
Full year 2025 earnings: EPS misses analyst expectations Full year 2025 results: EPS: UK£0.017 (up from UK£0.008 in FY 2024). Revenue: UK£48.7m (up 17% from FY 2024). Net income: UK£7.00m (up 106% from FY 2024). Profit margin: 14% (up from 8.1% in FY 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 15%. Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings. Aankondiging • Mar 25
Niox Group plc Recommends Final Dividend for the Year Ended 31 December 2025 NIOX Group Plc announced that the Board recommended the payment of a final dividend of 1.55 pence per fully paid ordinary share (2024: 1.25 pence). The aggregate amount of the proposed dividend expected to be paid after the reporting date, out of retained earnings at 31 December 2025, but not recognized as a liability at year end is £6.5 million (2024: £5.0 million). Aankondiging • Mar 20
NIOX Group Plc to Report Fiscal Year 2025 Results on Mar 24, 2026 NIOX Group Plc announced that they will report fiscal year 2025 results on Mar 24, 2026 Reported Earnings • Sep 30
First half 2025 earnings released: EPS: UK£0.014 (vs UK£0.01 in 1H 2024) First half 2025 results: EPS: UK£0.014 (up from UK£0.01 in 1H 2024). Revenue: UK£25.2m (up 20% from 1H 2024). Net income: UK£5.90m (up 34% from 1H 2024). Profit margin: 23% (up from 21% in 1H 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.6% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Medical Equipment industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has increased by 26% per year, which means it is well ahead of earnings. Aankondiging • Jul 08
NIOX Group Plc to Report First Half, 2025 Results on Sep 30, 2025 NIOX Group Plc announced that they will report first half, 2025 results on Sep 30, 2025 Declared Dividend • Apr 04
Dividend increased to UK£0.013 Dividend of UK£0.013 is 25% higher than last year. Ex-date: 15th May 2025 Payment date: 16th June 2025 Dividend yield will be 1.7%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is well covered by both earnings (38% earnings payout ratio) and cash flows (25% cash payout ratio). The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. EPS is expected to grow by 142% over the next 2 years, which should provide support to the dividend and adequate earnings cover. Aankondiging • Apr 03
Niox Group plc Recommends Final Dividend for the Year Ended December 31, 2024 NIOX Group Plc recommended final dividend of 1.25 pence per share in respect of the year ended December 31 2024. New Risk • Apr 01
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 8.1% Last year net profit margin: 26% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Profit margins are more than 30% lower than last year (8.1% net profit margin). Reported Earnings • Apr 01
Full year 2024 earnings: EPS misses analyst expectations Full year 2024 results: EPS: UK£0.008 (down from UK£0.023 in FY 2023). Revenue: UK£41.8m (up 14% from FY 2023). Net income: UK£3.40m (down 64% from FY 2023). Profit margin: 8.1% (down from 26% in FY 2023). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 69%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 29% per year, which means it is well ahead of earnings. Aankondiging • Mar 21
An unknown funds managed by Keensight Capital made a proposal to acquire NIOX Group Plc (AIM:NIOX) for approximately £320 million. An unknown funds managed by Keensight Capital made a proposal to acquire NIOX Group Plc (AIM:NIOX) for approximately £320 million on February 20, 2025. As on March 6, 2025, The Board of NIOX Group received a revised proposal from Keensight Capital on behalf of funds managed or advised by it ("Keensight") regarding a possible cash offer to acquire the entire issued and to be issued ordinary share capital of NIOX (the "Proposal") at an offer price of £0.81 per NIOX share, the Proposal follows a previous unsolicited approach by Keensight to acquire NIOX on February 20, 2025 at an offer price of £0.78 per NIOX share. The Proposal is subject to the satisfaction or waiver by Keensight of a number of pre-conditions, including the completion of satisfactory due diligence. Accordingly, the Board has agreed to provide Keensight with access to due diligence. Discussions with Keensight remain at a preliminary stage and, as such, there can be no certainty that any firm offer will be made for the Company by Keensight, nor as to the terms of any such offer, should one be made.
Lazard & Co., Limited and Singer Capital Markets Advisory LLP acted as financial advisor to NIOX. New Risk • Mar 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Aankondiging • Jan 17
NIOX Group Plc, Annual General Meeting, May 14, 2025 NIOX Group Plc, Annual General Meeting, May 14, 2025. Aankondiging • Dec 04
NIOX Group Plc to Report Fiscal Year 2024 Results on Apr 01, 2025 NIOX Group Plc announced that they will report fiscal year 2024 results at 8:00 AM, GMT Standard Time on Apr 01, 2025 Reported Earnings • Sep 26
First half 2024 earnings released: EPS: UK£0.01 (vs UK£0.007 in 1H 2023) First half 2024 results: EPS: UK£0.01 (up from UK£0.007 in 1H 2023). Revenue: UK£21.0m (up 12% from 1H 2023). Net income: UK£4.40m (up 52% from 1H 2023). Profit margin: 21% (up from 15% in 1H 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth. Aankondiging • Sep 24
NIOX Group Plc (AIM:NIOX) announces an Equity Buyback for 26,250,000 shares, representing 6.19% for £21 million. NIOX Group Plc (AIM:NIOX) announces a share repurchase program. Under the program, the company will repurchase up to 26,250,000 shares, representing 6.19% of its share capital for £21 million. The shares will be repurchased at £0.8 per share. The company intends to hold 10,000,000 shares in treasury and the remaining shares will be cancelled. The record date for the offer is October 15, 2024. The offer will be valid till October 15, 2024. The tender offer is subject to approval from shareholders in the Extraordinary General Meeting to be held on October 16, 2024. As of September 23, 2024, the company has 424,045,460 shares in issue. Aankondiging • Aug 19
NIOX Group Plc to Report First Half, 2024 Results on Sep 24, 2024 NIOX Group Plc announced that they will report first half, 2024 results on Sep 24, 2024 Aankondiging • Jul 01
Niox Group plc Appoints Robert Naylor as Non-Executive Director and Chair of the Audit and Risk Committee NIOX Group plc announced the appointment of Robert Naylor, aged 49, as Non-Executive Director and Chair of the Audit and Risk Committee, with immediate effect. Robert has over 25 years' experience in capital markets specialising in healthcare and investment companies and is currently Chief Executive Officer of Intuitive Investments Group plc, an investment company which is quoted on the Specialist Fund Segment of the London Stock Exchange's Main Market, providing investors with exposure to a portfolio of fast-growing technology and life sciences businesses. Additionally, Robert is Non-Executive Chairman of Hipgnosis Songs Fund Limited, a FTSE 250 company, which is currently subject to a recommended cash offer by Lyra Bidco Limited, a newly-formed company indirectly wholly-owned by investment funds advised by affiliates of Blackstone Inc. Previously, Robert was Non-Executive Chairman of Round Hill Music Royalty Fund Limited and oversaw its sale to a company directly owned by Alchemy Copyrights, LLC, trading as Concord. He has also served as a Non-Executive Director of Light Science Technologies Holdings plc, an AIM-quoted controlled environment agriculture company. Earlier in his career Robert held various positions within JP Morgan Asset Management Limited, Panmure Gordon (UK) Limited and Cenkos Securities plc. Robert is a qualified chartered accountant, having started his career with Ernst & Young in 1996. Current directorships/partnerships: Intuitive Investments Group Plc, IIG Assets Ltd, Hipgnosis SFH XX Limited, Hipgnosis SFH XIII Limited, Hipgnosis SFH XIX Limited, Hipgnosis SFH I Limited, Hipgnosis Holdings UK Limited, Rubyruby (London) Limited, Pb Songs Ltd, Kennedy Publishing & Productions Limited, Deamon Limited. Past directorships/partnerships: Round Hill Music Royalty Fund Limited, RHMRF2 Limited, RHMRF3 Limited, Light Science Technologies Holdings plc, Concord Copyrights No.1 Limited (formerly RHMRF1 Limited). Upcoming Dividend • May 16
Upcoming dividend of UK£0.01 per share Eligible shareholders must have bought the stock before 23 May 2024. Payment date: 24 June 2024. Trailing yield: 1.4%. Lower than top quartile of British dividend payers (5.7%). Lower than average of industry peers (2.5%). Aankondiging • Apr 05
NIOX Group Plc Proposes Final Dividend for the Financial Year Ended 31 December 2023, Payable on 24 June 2024 NIOX Group Plc announced on 26 March 2024 a proposed final dividend of 1.0 pence per ordinary share in respect of the financial year ended 31 December 2023. The proposed dividend is subject to shareholder approval at the Company's Annual General Meeting ("AGM") to be held on 22 May 2024. Following approval, the dividend will be paid on 24 June 2024 to shareholders on the register at the close of business on the record date of 24 May 2024, with an ex-dividend date of 23 May 2024. Recent Insider Transactions • Mar 31
COO & Executive Director recently sold UK£146k worth of stock On the 28th of March, Jonathan Emms sold around 234k shares on-market at roughly UK£0.62 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Jonathan's only on-market trade for the last 12 months. Reported Earnings • Mar 27
Full year 2023 earnings: Revenues in line with analyst expectations Full year 2023 results: Revenue: UK£36.8m (up 18% from FY 2022). Net income: UK£9.50m (down 33% from FY 2022). Profit margin: 26% (down from 45% in FY 2022). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in the United Kingdom. Price Target Changed • Oct 05
Price target increased by 7.1% to UK£0.79 Up from UK£0.74, the current price target is an average from 4 analysts. New target price is 19% above last closing price of UK£0.66. Stock is up 83% over the past year. The company is forecast to post earnings per share of UK£0.024 for next year compared to UK£0.034 last year. Reported Earnings • Sep 28
First half 2023 earnings released: EPS: UK£0.007 (vs UK£0.021 in 1H 2022) First half 2023 results: EPS: UK£0.007 (down from UK£0.021 in 1H 2022). Revenue: UK£18.8m (up 21% from 1H 2022). Net income: UK£2.90m (down 67% from 1H 2022). Profit margin: 15% (down from 57% in 1H 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has only increased by 38% per year, which means it is significantly lagging earnings growth. New Risk • Sep 27
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 23% Last year net profit margin: 46% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.1% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (23% net profit margin). Price Target Changed • Aug 04
Price target increased by 8.8% to UK£0.78 Up from UK£0.72, the current price target is an average from 3 analysts. New target price is 14% above last closing price of UK£0.69. Stock is up 92% over the past year. The company is forecast to post earnings per share of UK£0.024 for next year compared to UK£0.034 last year. Major Estimate Revision • Jul 27
Consensus EPS estimates increase by 20% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from UK£37.2m to UK£37.7m. EPS estimate increased from UK£0.02 to UK£0.024 per share. Net income forecast to shrink 28% next year vs 2.3% growth forecast for Biotechs industry in the United Kingdom . Consensus price target up from UK£0.72 to UK£0.74. Share price was steady at UK£0.69 over the past week. Aankondiging • Jul 21
NIOX Group Plc Announces Special Dividend, Payable on 15 September 2023 NIOX Group Plc announced a special dividend of 2.5 pence per share (equating to a return of cash of approximately £10.5 million) will be paid on 15 September 2023 to shareholders on the register as at the close of business on Friday 18 August 2023. The Group is now generating sufficient operating cashflow to permit both continued investment in the development of its business and the payment of ongoing dividends to shareholders. Major Estimate Revision • Jul 12
Consensus EPS estimates increase by 40% The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate increased from UK£0.015 to UK£0.021. Revenue forecast steady at UK£37.2m. Net income forecast to shrink 36% next year vs 2.5% growth forecast for Biotechs industry in the United Kingdom . Consensus price target up from UK£0.69 to UK£0.71. Share price rose 5.3% to UK£0.61 over the past week. Buying Opportunity • Jun 08
Now 22% undervalued Over the last 90 days, the stock is up 27%. The fair value is estimated to be UK£0.79, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 14% per annum. Earnings is forecast to decline by 2.9% per annum over the same time period. Aankondiging • Jun 07
NIOX Group Plc Announces Special Dividend, Payable on 15 September 2023 NIOX Group Plc announced that a special dividend of 2.5 pence per ordinary share will be paid on 15 September 2023 to shareholders on the register as at 18 August 2023. The associated ex-dividend date will be 17 August 2023. Major Estimate Revision • May 25
Consensus EPS estimates fall by 41%, revenue upgraded The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from UK£36.4m to UK£36.8m. EPS estimate fell from UK£0.0135 to UK£0.008 per share. Net income forecast to shrink 76% next year vs 6.8% growth forecast for Biotechs industry in the United Kingdom . Consensus price target up from UK£0.56 to UK£0.67. Share price was steady at UK£0.59 over the past week. Board Change • Apr 02
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Non-Independent Non-Executive Director Nick Mills was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Recent Insider Transactions • Mar 30
COO & Executive Director recently sold UK£100k worth of stock On the 28th of March, Jonathan Emms sold around 227k shares on-market at roughly UK£0.44 per share. This transaction amounted to 24% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Jonathan's only on-market trade for the last 12 months. Major Estimate Revision • Mar 28
Consensus EPS estimates increase by 108% The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate increased from UK£0.0065 to UK£0.0135. Revenue forecast steady at UK£36.4m. Net income forecast to shrink 58% next year vs 11% decline forecast for Biotechs industry in the United Kingdom. Consensus price target up from UK£0.49 to UK£0.55. Share price was steady at UK£0.47 over the past week. Reported Earnings • Mar 21
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2022 results: EPS: UK£0.034 (up from UK£0.006 in FY 2021). Revenue: UK£31.3m (up 12% from FY 2021). Net income: UK£14.1m (up UK£11.8m from FY 2021). Profit margin: 45% (up from 8.2% in FY 2021). The increase in margin was primarily driven by lower expenses. Revenue missed analyst estimates by 1.6%. Earnings per share (EPS) exceeded analyst estimates by 91%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has only increased by 47% per year, which means it is significantly lagging earnings growth. Aankondiging • Jan 17
NIOX Group Plc to Report Fiscal Year 2022 Results on Mar 21, 2023 NIOX Group Plc announced that they will report fiscal year 2022 results on Mar 21, 2023 Price Target Changed • Nov 16
Price target increased to UK£0.48 Up from UK£0.43, the current price target is an average from 3 analysts. New target price is 29% above last closing price of UK£0.37. Stock is down 11% over the past year. The company is forecast to post earnings per share of UK£0.019 for next year compared to UK£0.0056 last year. Board Change • Oct 31
High number of new directors Non-Independent Non-Executive Director Nick Mills was the last director to join the board, commencing their role in 2020. Price Target Changed • Oct 13
Price target increased to UK£0.48 Up from UK£0.43, the current price target is an average from 2 analysts. New target price is 31% above last closing price of UK£0.36. Stock is down 18% over the past year. The company is forecast to post earnings per share of UK£0.021 for next year compared to UK£0.0056 last year. Reported Earnings • Sep 16
First half 2022 earnings released: EPS: UK£0 (vs UK£0.005 loss in 1H 2021) First half 2022 results: EPS: UK£0 (improved from UK£0.005 loss in 1H 2021). Revenue: UK£15.5m (up 6.2% from 1H 2021). Net income: UK£8.90m (up UK£10.9m from 1H 2021). Profit margin: 57% (up from net loss in 1H 2021). The move to profitability was primarily driven by lower expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the United Kingdom. Price Target Changed • Sep 05
Price target increased to UK£0.47 Up from UK£0.43, the current price target is an average from 2 analysts. New target price is 38% above last closing price of UK£0.34. Stock is down 11% over the past year. The company is forecast to post earnings per share of UK£0.021 for next year compared to UK£0.0056 last year. Major Estimate Revision • Jul 30
Consensus forecasts updated The consensus outlook for 2022 has been updated. Biotechs industry in the United Kingdom expected to see average net income decline 33% next year. Consensus price target broadly unchanged at UK£0.44. Share price was steady at UK£0.35 over the past week. Price Target Changed • Apr 27
Price target increased to UK£0.46 Up from UK£0.08, the current price target is an average from 2 analysts. New target price is 29% above last closing price of UK£0.35. Stock is down 2.6% over the past year. The company is forecast to post earnings per share of UK£0.002 for next year compared to UK£0.0056 last year. Board Change • Apr 27
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Non-Independent Non-Executive Director Nick Mills was the last director to join the board, commencing their role in 2020. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Recent Insider Transactions • Apr 02
Executive Chairman recently bought UK£54k worth of stock On the 29th of March, Ian Johnson bought around 150k shares on-market at roughly UK£0.36 per share. This was the largest purchase by an insider in the last 3 months. Ian has been a buyer over the last 12 months, purchasing a net total of UK£167k worth in shares. Recent Insider Transactions • Sep 18
Executive Chairman recently bought UK£56k worth of stock On the 16th of September, Ian Johnson bought around 150k shares on-market at roughly UK£0.37 per share. This was the largest purchase by an insider in the last 3 months. Ian has been a buyer over the last 12 months, purchasing a net total of UK£113k worth in shares. Reported Earnings • Sep 18
First half 2021 earnings released: UK£0.005 loss per share (vs UK£0.027 loss in 1H 2020) The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: UK£14.6m (up 28% from 1H 2020). Net loss: UK£2.00m (loss narrowed 79% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings. Recent Insider Transactions • Apr 07
Executive Chairman recently bought UK£58k worth of stock On the 6th of April, Ian Johnson bought around 200k shares on-market at roughly UK£0.29 per share. This was the largest purchase by an insider in the last 3 months. Ian has been a buyer over the last 12 months, purchasing a net total of UK£103k worth in shares. Reported Earnings • Mar 26
Full year 2020 earnings released: UK£0.072 loss per share (vs UK£0.13 loss in FY 2019) The company reported a soft full year result with weaker revenues and control over costs, although losses reduced. Full year 2020 results: Revenue: UK£23.9m (down 62% from FY 2019). Net loss: UK£26.8m (loss narrowed 45% from FY 2019). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Feb 22
New 90-day low: UK£0.24 The company is down 22% from its price of UK£0.30 on 24 November 2020. The British market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 34% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£0.052 per share. Price Target Changed • Feb 04
Price target raised to UK£0.21 Up from UK£0.08, the current price target is an average from 2 analysts. The new target price is 22% below the current share price of UK£0.27. As of last close, the stock is down 6.6% over the past year. 
